Revenue Cycle Vendors That Specialize in Infusion and Specialty Pharmacy Denial Management

Payer-specific root-cause denial management for infusion claims means tracing each denial to the payer rule, authorization gap, coding error, or coverage lapse that caused it, then correcting the upstream process. Revenue cycle vendors serving infusion and specialty pharmacy should be evaluated on that capability. Their workflows need to be built for treatments that recur, the risk of unpaid drug costs, and checks that payments are correct.

Why infusion denial management is structurally different from general medical billing

A single infusion visit can fail at at least five independent points, including authorization status, J-code accuracy, unit calculation, NDC matching, and administration code sequencing. Any one can stop payment on its own. These failure modes occur together in a workflow where charges can run from thousands to tens of thousands of dollars, making a coding error or authorization lapse a cash-flow event.

The practice has already purchased and administered the drug when it submits the claim, so a denial leaves acquisition cost unpaid. That puts more money at risk as the practice gives more treatments. BrightSpring Health Services’ H1 2026 10-Q reported that specialty and infusion pharmacy revenues were up sharply year-over-year because there were more specialty branded drug prescriptions. A vendor that handles denials generically cannot address combined failure modes it was never designed to see.

The four failure modes that define infusion denial risk

Infusion denial risk clusters around four failure modes, which are authorization lifecycle gaps, J-code and unit errors, site-of-care and step-therapy payer behavior, and coverage lapse exposure. Each needs a different operational response. Authorization gaps arise because recurring treatment requires approval at payer-defined intervals. Tighter timelines, lab-work requirements before each cycle, and dosage-adjustment caps can turn a previously approved treatment into a denied claim.

J-code and unit errors come from translating clinical dosing into billable quantities. Drug units must equal the administered dose divided by the J-code unit size, and dose changes, split vials, or rounding can disrupt that translation. Site-of-care rules can require proof of clinical necessity again, while step therapy can require proof that another drug failed. Neither problem is solved by correcting a drug code.

Coverage lapse exposure is distinct from those approval and coding problems. Specialty drug coverage changes frequently, so a short verification gap can expose a practice to a full write-off on a high-cost biologic that was previously covered. Earlier payment offers no protection against that gap. These four failure modes are predictable properties of infusion billing. A vendor’s capabilities need to match each one.

Why prior authorization for recurring infusion treatments is an ongoing lifecycle problem, not a one-time approval

The first approval is only the starting point. Recurring infusion requires authorization to remain aligned with the treatment schedule, payer deadlines, clinical documentation, and any dose changes. When authorization is treated as a completed task rather than an ongoing process, a lapse can interrupt both treatment and reimbursement.

SamaCare’s 2022 survey found that the vast majority of infusion providers said the authorization process had harmed patient care. Over half of referrals to infusion providers do not convert to patients, often because slow turnarounds lead patients to seek care elsewhere. Only about half of infusion providers appeal treatment denials on a regular basis, so many denied requests go unchallenged. Electronic prior authorization can substantially reduce staff time spent on these tasks, but a buyer still needs to distinguish authorization software from broader pre-treatment support.

SamaCare is purpose-built for medical-benefit, J-code prior authorization. Its AI platform is trained on a large volume of prior authorizations and designed for the buy-and-bill approval workflow. Mandolin covers a broader pre-treatment scope for infusion centers and specialty pharmacies. Its agentic platform handles prior authorization, benefits investigation, patient cost estimation, co-pay assistance coordination, and drug pricing programs. Managing an approval request and coordinating the surrounding specialty-drug workflow are different purchasing needs.

Buy-and-bill J-code complexity and the unit-count error that silently erodes revenue

Under buy-and-bill, the provider purchases the drug and bills for both the drug and its administration. Under white-bagging, the payer’s specialty pharmacy ships the drug, and the facility bills only for administration. A practice must track which payers require which model. In buy-and-bill, that distinction is especially consequential because drug reimbursement must follow an acquisition cost the practice has already incurred.

Within that model, an incorrect unit count can cause harm without producing a denial. The calculation is straightforward in principle. The administered dose is divided by the J-code unit size, but the arithmetic can happen outside the billing system and enter the claim without further validation. Dose adjustments, split vials, and rounding at the point of care make this handoff vulnerable. When an understated unit count produces a paid-but-underpaid claim, the error attracts less attention than a rejection.

That is why payment alone is a weak test of accuracy. If the same calculation problem recurs across a therapy, the revenue loss becomes systematic. The relevant vendor capability is validation against the administered dose and J-code unit size.

A newly approved biologic may require a not-otherwise-classified code or a temporary Q-code before it receives a permanent J-code. Reimbursement can then be based on wholesale acquisition cost until average sales price data catches up, typically two quarters later. Biosimilars also have distinct J-codes, and using a reference product’s code for a biosimilar, or the reverse, creates denial and audit risk. Drugs bought through federal discount programs need specific modifiers and must be tracked separately, and errors in billing can expose the practice to audits and recoupment demands.

How underpayments hide in infusion remittances and why most practices never find them

An underpayment does not always arrive labeled as a problem. Payers can post it as a contractual adjustment, allowing a claim to pass through standard accounts receivable review as closed. The unpaid amount then becomes a permanent write-off unless someone compares the remittance with the contracted rate at the procedure-code level. General workflows often focus their tracking on denial rates.

Finding patterns requires more than reviewing one short-paid claim. SolisRx uses Claim Adjustment Reason Code concentration analysis to study revenue cycle data from 24 or more months. It groups denied and underpaid claims by reason code, then cross-references payer, therapy type, site, and submission date. The resulting clusters can point to a small number of recurring upstream causes. Each cluster needs a way to fix its cause instead of being handled through the usual collections process.

The same distinction helps clarify vendor scope. SolisRx provides infusion-specific analytics, including authorization expiration monitoring before treatment and a payer performance scorecard comparing expected with actual reimbursement by payer and site. MD Clarity addresses underpayment, variance, and payer contract recovery analytics. Black Book Research’s 2026 report rated it the top vendor in that category, a category-specific finding rather than a ranking of complete infusion RCM coverage.

How do you stop recurring infusion denials from the same payers?

An aggregate denial rate shows frequency. It cannot establish whether a practice’s losses come from one payer’s site-of-care policy, a unit calculation affecting one therapy, or reauthorization lapses at a particular treatment interval. Those patterns demand different remedies. Payer-specific root-cause analysis therefore needs to separate claims by payer, therapy, cause, and submission date, with geography included where coverage decisions vary by location.

Step-therapy and fail-first policies show why that detail is necessary. Published coverage policies and real-world authorization decisions can diverge by health plan, therapy type, and geography. Practice-wide totals conceal those differences. Providence Health Plan’s site-of-care redirection policies, for example, require documentation of continued clinical necessity at defined intervals. Tracking those payer-policy deadlines creates a chance to prevent the lapse, while a system that starts work only after denial sees the problem too late.

The vendor test is whether analysis changes the response. A step-therapy denial calls for a different path from a unit-count error or a coverage lapse, even when all three appear in the same denial report. SolisRx’s payer and site scorecards illustrate the granularity needed to distinguish reimbursement patterns, while SamaCare’s medical-benefit focus and Mandolin’s broader pre-treatment scope address different parts of the authorization workflow. None of those descriptions alone establishes complete denial-management coverage. The buyer needs to see how a vendor connects its particular capability to the actual cause and prevents that cause from recurring.

What a purpose-built infusion RCM vendor actually covers, end to end

End-to-end control begins at scheduling, before a claim exists. By submission, authorization may already be at risk, coverage may have gone unverified, or an incorrect unit count may have entered the workflow. Benefits verification and prior authorization therefore belong before the treatment cycle, with active tracking of reauthorization deadlines by payer policy. For a buyer, the first question is where the vendor’s responsibility begins. A vendor that starts at claim submission cannot prevent the failures that happen before then.

Claim preparation needs its own distinct controls. J-code unit validation, NDC matching, modifier accuracy, and administration code sequencing each address a separate reimbursement or compliance risk. That review needs to include discount-program modifiers when they apply. If a denial still occurs, the workflow needs appeal capacity and payer-specific root-cause tracking that feeds findings back into prevention. Fixing the current claim without changing the process puts the next treatment cycle at risk of the same problem.

Payment posting is another checkpoint. Remittance reconciliation must check payments against contracted rates at the procedure-code level, even when a claim has been paid. Accounts receivable management then needs to prioritize by claim value and payer alongside days outstanding. A high-value biologic claim in mid-range aging calls for different urgency from a low-value office visit in the same aging bucket. Complete coverage joins these stages, so scheduling, authorization, coding, denials, reconciliation, and collections do not operate as disconnected tasks.

How to evaluate whether a vendor's infusion specialization is structural or superficial

For a practice evaluating vendors, the questions should follow those failure points. Does the authorization workflow track reauthorization deadlines by payer policy and therapy, or begin only after a denial? Is dedicated authorization staff trained in the clinical criteria for infusion therapies? Knowing which records a payer requires can take judgment that a general billing queue does not provide.

The next test is what happens before submission. Does the vendor validate drug units against the administered dose and J-code unit size, or simply submit the practice’s quantity? Does it track biosimilar assignments and flag transitional NOC or Q-code situations? Those questions distinguish validation from data entry.

Can the vendor break patterns down by payer, therapy, root cause, and submission date, and distinguish preventable problems from those that require appeal? Does it reconcile contracted rates at the procedure-code level, or post remittances and close claims? Ask about the human escalation path as well. Infusion-specialized operators need a way to address payer criteria and clinical documentation cases that automated rules cannot resolve.

SamaCare, Mandolin, SolisRx, and MD Clarity illustrate different scopes within this capability set, from medical-benefit authorization to broader pre-treatment coordination and payment analytics. A shortlist should make those boundaries explicit. The right fit depends on which failure points the practice needs covered and how the vendor connects them.